Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
J Urol ; 195(1): 41-6, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26307162

ABSTRACT

PURPOSE: The optimal dose of intravesical bacillus Calmette-Guérin for the treatment of nonmuscle invasive bladder cancer is controversial. We investigated if induction therapy with low dose bacillus Calmette-Guérin could achieve a complete response rate similar to that of standard dose bacillus Calmette-Guérin, with less toxicity and higher quality of life. MATERIALS AND METHODS: After transurethral resection, patients with unresectable multiple nonmuscle invasive bladder cancer and/or carcinoma in situ were randomized to receive standard (80 mg) or low dose (40 mg) bacillus Calmette-Guérin instillation induction therapy (weekly, 8 times). The primary end point was noninferiority of low dose bacillus Calmette-Guérin with a null hypothesis of a 15% decrease in complete response rate. Secondary end points were recurrence-free survival, progression-free survival, overall survival, patient compliance, adverse events and quality of life using the EORTC QLQ-C30. RESULTS: In an intent to treat analysis of 166 patients the complete response rates for low dose and standard dose bacillus Calmette-Guérin were 79% (95% CI 0.70-0.88) and 85% (95% CI 0.77-0.92), respectively. Dunnett-Gent analysis revealed that the null hypothesis of inferiority of low dose bacillus Calmette-Guérin in terms of complete response could not be rejected (p = 0.119). However, there were no significant differences between the groups in terms of recurrence, progression and overall survival. Low dose bacillus Calmette-Guérin was associated with significantly less fever (p = 0.001) and micturition pain (p = 0.047), and significantly higher quality of life scores for global quality of life, role functioning and functional impairment. CONCLUSIONS: The noninferiority of low dose bacillus Calmette-Guérin was not proven. However, low dose bacillus Calmette-Guérin was associated with lower toxicity and higher quality of life compared to standard dose bacillus Calmette-Guérin in patients with nonmuscle invasive bladder cancer.


Subject(s)
Adjuvants, Immunologic/administration & dosage , BCG Vaccine/administration & dosage , Quality of Life , Urinary Bladder Neoplasms/drug therapy , Adjuvants, Immunologic/adverse effects , Administration, Intravesical , Aged , BCG Vaccine/adverse effects , Female , Humans , Male , Neoplasm Invasiveness , Treatment Outcome , Urinary Bladder Neoplasms/pathology
2.
Anticancer Res ; 34(4): 1983-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24692735

ABSTRACT

AIM: To determine the treatment outcome of combined androgen blockade (CAB) therapy using the non-steroidal antiandrogen bicalutamide or the steroidal antiandrogen chlormadinone in patients with prostate cancer. PATIENTS AND METHODS: In total, 124 patients with prostate cancer enrolled in the present study were randomized to receive CAB therapy using a gonadotropin-releasing hormone (GnRH) agonist, combined with bicalutamide or chlormadinone. The survival of patients was analyzed. RESULTS: The 5-year cancer-specific survival for the bicalutamide- and chlormadinone-treated groups were 91.7% and 86.6%, respectively, with no significant difference (p=0.39). Five-year overall survival was significantly (p=0.029) better in the bicalutamide-treated group. Moreover, M1 patients in the chlormadinone group had significantly lower cancer-specific and overall survival compared to those in the bicalutamide-treated group. However, in the case of M0 patients, no significant difference in cancer-specific nor in overall survival was observed. CONCLUSION: CAB therapy using chlormadinone led to a significantly poorer survival outcome versus the use of bicalutamide. However, because this survival trend was not observed in M0 cases, chlormadinone may still be an option for CAB therapy, depending on clinical stage and the severity of adverse effects, such as hot flashes.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Androgen Antagonists/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Gonadotropin-Releasing Hormone/administration & dosage , Humans , Male , Neoplasm Grading , Neoplasm Staging , Prospective Studies , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Treatment Outcome
3.
Int J Clin Oncol ; 18(1): 68-74, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22068465

ABSTRACT

BACKGROUND: The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan. METHODS: The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival. RESULTS: From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group. CONCLUSION: Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.


Subject(s)
Carcinoma, Renal Cell/drug therapy , Interferon-alpha/administration & dosage , Kidney Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Recombinant Proteins/administration & dosage , Adult , Aged , Aged, 80 and over , Angiogenesis Inhibitors/administration & dosage , Carcinoma, Renal Cell/pathology , Disease-Free Survival , Humans , Interferon-alpha/adverse effects , Japan , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Middle Aged , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/pathology , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Nephrectomy , Treatment Outcome
4.
Cancer Chemother Pharmacol ; 70(3): 451-9, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22864875

ABSTRACT

PURPOSE: The prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen. We administered combination therapy with low-dose gemcitabine (GEM) and paclitaxel (PTX), named low-dose gemcitabine-paclitaxel (LD-GP) therapy, as salvage therapy for these patients. The aim was to evaluate the anti-tumoral effects, relief of pain, and toxicity of LD-GP therapy in patients with resistance to CDDP-containing therapy. PATIENTS AND METHODS: Thirty-five patients with advanced UC, previously treated with CDDP-containing regimens, were treated with LD-GP therapy (GEM, 700 mg/m(2) + PTX, 70 mg/m(2) on day 1 and 8, repeated every 28 days). Pain was measured on a visual analog scale before and after treatment. Pain relief and survival were compared between this and other treatment regimens. RESULTS: None of the patients had complete response to LD-GP therapy. Partial response and stable disease were seen in 25.7 and 62.9 % of patients, respectively. Kaplan-Meier curves showed better survival in patients with LD-GP therapy than with others (p = 0.034). Twenty-eight patients (80.0 %) had adequate pain relief, and only two patients needed to increase their analgesics. Other regimens demonstrated pain relief in 30.4 % of patients. Common toxicities included leukopenia, with five patients requiring granular colony-stimulating factor therapy (14.3 %). The most common non-hematologic toxicity was fatigue (n = 7, 17.1 %). CONCLUSIONS: LD-GP therapy is feasible and well tolerated as salvage therapy in patients with advanced UC with resistance to CDDP-containing therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pain/drug therapy , Urologic Neoplasms/drug therapy , Urothelium/pathology , Aged , Analgesics/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Drug Resistance, Neoplasm , Feasibility Studies , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Paclitaxel/administration & dosage , Pain/etiology , Pain Measurement , Retrospective Studies , Salvage Therapy/methods , Treatment Outcome , Urologic Neoplasms/pathology , Gemcitabine
5.
Gan To Kagaku Ryoho ; 39(2): 321-3, 2012 Feb.
Article in Japanese | MEDLINE | ID: mdl-22333653

ABSTRACT

A 74-year-old female patient with bladder cancer presented with edema in the right lower limb in a follow-up at the outpatient department.She was diagnosed with deep vein thrombosis in the right lower limb, and warfarin treatment was started.Subsequent gemcitabine and cisplatin combination(GC)therapy for prevention of bladder cancer recurrence prolonged the PT-INR to an immeasurable level on day 6 of therapy.Thus, warfarin was immediately discontinued and a single dose of menatetrenone was administered.Subsequently, the PT-INR recovered to 1.36 one day after discontinuation of warfarin.In the second course of GC therapy, warfarin was discontinued before administration of the anticancer drugs, and there was no change in the PT-INR.The abnormally high PT-INR observed in the early stage after GC therapy in this case shows that it is important to monitor blood coagulation from immediately after administration of GC therapy in a patient under treatment with warfarin.


Subject(s)
Anticoagulants/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Thrombophlebitis/drug therapy , Urinary Bladder Neoplasms/drug therapy , Warfarin/therapeutic use , Aged , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Edema/etiology , Female , Humans , International Normalized Ratio , Leg , Prothrombin/metabolism , Thrombophlebitis/complications , Thrombophlebitis/enzymology , Gemcitabine
6.
Hinyokika Kiyo ; 57(1): 7-13, 2011 Jan.
Article in Japanese | MEDLINE | ID: mdl-21304253

ABSTRACT

A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.


Subject(s)
Adrenergic alpha-Antagonists/administration & dosage , Naphthalenes/administration & dosage , Piperazines/administration & dosage , Prostatic Hyperplasia/drug therapy , Urinary Bladder, Overactive/drug therapy , Adrenergic alpha-Antagonists/adverse effects , Aged , Aged, 80 and over , Drug Administration Schedule , Humans , Male , Middle Aged , Naphthalenes/adverse effects , Piperazines/adverse effects , Prostatic Hyperplasia/complications , Urinary Bladder, Overactive/etiology
7.
Cancer Epidemiol ; 34(3): 350-4, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20362526

ABSTRACT

BACKGROUND: Green tea polyphenol (GTP) suppresses malignancy in bladder cancer cell lines. However, the detail of its anti-carcinogenic effect in vivo is not fully understood. This study investigated the effect of GTP on bladder tumor size and angiogenesis in mice given N-butyl-(-4-hydroxybutyl) nitrosamine (BBN), with and without GTP. METHODS: Eight-week-old female C3H/He mice were treated with and without 0.05% BBN solution for 14 or 24 weeks. In addition, they were also treated with and without 0.5% GTP solution for the same periods. Histopathological diagnosis was established using hematoxylin and eosin staining, and microvessel density (MVD) was estimated by counting CD34- and von Willebrand factor-positive vessels in the tumor area. RESULTS: At 14 weeks, cancer cells were detected in BBN and BBN+GTP mice [5/14 (35.7%) and 3/14 (21.4%), respectively, p=0.678]. At 24 weeks, the incidence of cancer cells was also similar between the groups (BBN+GTP: 61.9% vs. BBN: 82.6%; p=0.179). However, the frequency of invasive tumors in BBN+GTP mice was significantly lower (23.8%; p=0.030) than in those given BBN alone (65.2%). Tumor volume and MVD of intratumoral and stromal region in the BBN+GTP group were also significantly lower than in BBN mice. CONCLUSION: The results showed that GTP had no anti-carcinogenic effect, but inhibited tumor growth and invasion in mice with established bladder cancer, at least in part through the regulation of angiogenesis. Our data suggest that GTP seems to suppress tumor development in bladder cancer.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Camellia sinensis , Flavonoids/therapeutic use , Phenols/therapeutic use , Plant Extracts/therapeutic use , Urinary Bladder Neoplasms/drug therapy , Animals , Butylhydroxybutylnitrosamine , Female , Mice , Neoplasm Invasiveness , Polyphenols , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/pathology
8.
Pathol Res Pract ; 205(1): 57-61, 2009.
Article in English | MEDLINE | ID: mdl-18930356

ABSTRACT

TFE3-renal carcinoma is rare in adults. Patients with this disease often have a poor prognosis, because it has reached an advanced stage at presentation, and there is lack of an effective therapy. The exact mechanism of its malignant behavior is still unclear. In recent years, a significant relationship between TFE3 fusion protein and hepatocyte growth factor receptor (HGFR)/Met tyrosine kinase activity was reported in several malignancies. We previously reported that phosphorylation of HGFR/Met was associated with malignant aggressiveness and survival in patients with conventional RCC. Here, using immunohistochemical techniques, we examined two types of phosphorylated HGFR/Met (pY1234/1235 and pY1349) in a specimen of a 29-year-old man with TFE3-renal carcinoma. Strong expression of both proteins was detected in carcinoma cells, but not in normal kidney tissues. In addition, they were expressed more strongly in TFE3-renal carcinoma than in conventional RCC. Although tumor was diagnosed at T1N0M0 and the patient received radical nephrectomy, the tumor metastasized to multiple organs, and he died 2 years after surgery. We speculate that upregulated phosphorylation of HGFR/Met could be partly associated with the malignant aggressiveness and poor survival of this patient.


Subject(s)
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/analysis , Carcinoma, Renal Cell/chemistry , Gene Expression Regulation, Neoplastic , Kidney Neoplasms/chemistry , Proto-Oncogene Proteins/analysis , Receptors, Growth Factor/analysis , Adult , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Fatal Outcome , Humans , Immunohistochemistry , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Male , Neoplasm Metastasis , Neoplasm Staging , Nephrectomy , Phosphorylation , Proto-Oncogene Proteins c-met , Up-Regulation
9.
Int J Urol ; 14(7): 591-4, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17645599

ABSTRACT

OBJECTIVES: Combined cisplatin-based intra-arterial chemotherapy and radiotherapy is an effective treatment for patients with locally invasive bladder carcinoma. We report long-term follow-up data regarding definitive treatment of locally invasive bladder carcinoma, regardless of whether bladder preservation was possible. METHODS: The follow-up data from 24 patients (18 males and six females; aged, 31-85 years; median, 73 years) with invasive bladder carcinoma, between 1993 and 2003, was examined. The clinical stages of the patients ranged T2-T4, all N0M0, and involved 13 patients at T2 (T2a, T2b), seven patients at T3 and four patients at T4. Combined cisplatin-based intra-arterial chemotherapy and radiotherapy was performed. RESULTS: The 5-year overall survival rate and cancer-specific survival rate for all patients were 81.6% and 85.6%, respectively. When the patients were divided into complete response (CR) of 10 patients and non-CR groups of 14 patients, the 5-year overall survival rate for the CR group was 87.5%, while that of the non-CR group was 78.6% (P = 0.58). The tumor grade of the CR group was significantly lower than that of the non-CR group (P = 0.01). When the non-CR group was divided into radical cystectomy and non-radical cystectomy groups, the 5-year overall survival rate for the radical cystectomy group (100%) was higher than that of the non-radical cystectomy group (70%). CONCLUSION: This combined chemo-radiotherapy was effective for local invasive bladder carcinoma, leading to the possibility of bladder preservation using this therapy.


Subject(s)
Antineoplastic Agents/administration & dosage , Cisplatin/administration & dosage , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Neoplasm Invasiveness , Time Factors , Urinary Bladder Neoplasms/pathology
10.
Acta Histochem Cytochem ; 40(3): 69-75, 2007 Jul 03.
Article in English | MEDLINE | ID: mdl-17653298

ABSTRACT

Connexin43 (Cx43) is abundantly expressed in mammalian testes and implicated in the regulation of cell-to-cell interaction between germ cells and Sertoli cells, which is essential to the normal process of spermatogenesis. In the present study, we investigated the relation between Cx43 expression and the degree of spermatogenesis in infertile human testes. Immunohistochemical analysis of Cx43 was performed on testicular biopsies from 29 patients with azoospermia (n=23) and severe oligospermia (n=6), who gave informed consent to this experiment. The degree of testicular spermatogenesis was evaluated by Johnsen score. In the interstitium, immunostaining for Cx43 was localized to some focal parts of plasma membrane between neighboring Leydig cells. In seminiferous tubules with normal spermatogenesis, Cx43 expression was found between Sertoli cells and germ cells. However, Cx43 expression in maturation arrest was decreased and located mainly in the basal compartment of seminiferous tubules. Finally, there was a significant positive correlation between histological score of spermatogenesis and intensity of Cx43 (p=0.0294). These data suggest that the alteration of Cx43 expression may be involved in spermatogenic impairment, and that the communication between Sertoli cells and germ cells through Cx43 may be important for maturation of spermatogenesis.

11.
J Biol Chem ; 281(43): 32469-84, 2006 Oct 27.
Article in English | MEDLINE | ID: mdl-16943193

ABSTRACT

Calreticulin (CRT) is a multifunctional Ca(2+)-binding molecular chaperone in the endoplasmic reticulum. In mammals, the expression level of CRT differs markedly in a variety of organs and tissues, suggesting that CRT plays a specific role in each cell type. In the present study, we focused on CRT functions in the kidney, where overall expression of CRT is quite low, and established CRT-overexpressing kidney epithelial cell-derived Madin-Darby canine kidney cells by gene transfection. We demonstrated that, in CRT-overexpressing cells, the morphology was apparently changed, and the original polarized epithelial cell phenotype was destroyed. Furthermore, CRT-overexpressing cells showed enhanced migration through Matrigel-coated Boyden chamber wells, compared with controls. E-cadherin expression was significantly suppressed at the protein and transcriptional levels in CRT-overexpressing cells compared with controls. On the other hand, the expression of mesenchymal protein markers, such as N-cadherin and fibronectin, was up-regulated. We also found that the expression of Slug, a repressor of the E-cadherin promoter, was up-regulated by overexpression of CRT through altered Ca(2+) homeostasis, and this led to enhanced binding of Slug to the E-box element in the E-cadherin promoter. Thus, we conclude that CRT regulates the epithelial-mesenchymal transition-like change of cellular phenotype by modulating the Slug/E-cadherin pathway through altered Ca(2+) homeostasis in cells, suggesting a novel function of CRT in cell-cell interaction of epithelial cells.


Subject(s)
Cadherins/metabolism , Calreticulin/metabolism , Epithelial Cells/metabolism , Gene Expression Regulation , Kidney/cytology , Animals , Cadherins/genetics , Calreticulin/genetics , Cell Adhesion/genetics , Cell Adhesion/physiology , Cell Line , Cell Movement/genetics , Cell Movement/physiology , Cell Shape/genetics , Cell Shape/physiology , Dogs , Epithelial Cells/cytology , Gene Expression Regulation/genetics , Repressor Proteins/genetics , Repressor Proteins/metabolism , Subcellular Fractions/metabolism
12.
J Urol ; 176(1): 348-53, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16753442

ABSTRACT

PURPOSE: Lymph node metastasis is an important prognostic factor in many types of cancer. Recently several specific markers for lymphatic endothelium were developed that facilitate the quantification of lymphangiogenesis in human cancer tissues. We investigated the clinical and prognostic significance of lymphangiogenesis in patients with transitional cell carcinoma of the upper urinary tract. MATERIALS AND METHODS: We measured lymph vessel density and relative lymphatic vascular area in 125 specimens by quantitative immunohistochemical staining for D2-40 antibody (DakoCytomation, Glostrup, Denmark). These parameters were examined in the intratumor and peritumor areas, and measured using image analysis software. RESULTS: Peritumor lymph vessel density and peritumor lymphatic vascular area correlated with lymph node metastasis and tumor grade. In the intratumor area lymphatic vessels were detected in only 16.0% of specimens. However, the presence of intratumor lymphatic vessels was associated with lymph node metastasis (p = 0.002). Multivariate analysis identified high peritumor lymphatic vascular area and the presence of intratumor lymphatic vessels as significant and independent factors of metastasis-free survival after surgery (OR = 5.11, p = 0.020 and OR = 2.92, p = 0.025, respectively). Multivariate analysis also identified the presence of intratumor lymphatic vessels as the only independent predictive factor of cause specific survival (OR = 3.89, p = 0.049). CONCLUSIONS: Lymphangiogenesis may have important roles in tumor metastasis and survival in patients with transitional cell carcinoma of the upper urinary tract. Quantification of lymphatic vessels, especially peritumor lymphatic vascular area and intratumor lymphatic vessels, was useful for predicting metastasis-free survival. In addition, the presence of intratumor lymphatic vessels was an independent predictor of cause specific survival.


Subject(s)
Carcinoma, Transitional Cell/pathology , Kidney Neoplasms/pathology , Lymphangiogenesis , Ureteral Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/mortality , Disease-Free Survival , Female , Humans , Immunohistochemistry , Kidney Neoplasms/mortality , Lymphatic Metastasis , Lymphatic Vessels/pathology , Male , Middle Aged , Prognosis , Survival Rate , Ureteral Neoplasms/mortality
13.
Virchows Arch ; 448(6): 822-9, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16609907

ABSTRACT

The prostaglandin E2 receptor, EP4 receptor (EP4R), plays an important role in the development of transitional cell carcinoma of the upper urinary tract (TCC-UUT). However, the clinical significance of other EP receptors (EP1R-3R) is not clear. Furthermore, the pathological function of EP receptors in such patients is not understood. In the present study, we examined the expression of EP1R-3R in 101 TCC-UUT tissues by immunohistochemistry. Furthermore, we defined the relationship between cyclooxygenase (COX)-2 and EP receptor expression, proliferation index (PI), microvessel density (MVD), and expression of metalloproteinase-2 (MMP-2), urokinase-type plasminogen activator (uPA), and exon v6 containing CD44 isoform (CD44 v6) by multivariate analysis. The expression of EP1R, EP2R, and EP3R was positive in 20 (19.8%), 26 (25.7%), and 14 (13.9%) tumor samples, respectively. Expression of these receptors was not associated with pathological findings or survival. COX-2 and EP4R were independently associated with MVD and MMP-2, and uPA or PI and MMP-2, respectively. Other EP receptors were not influenced by any factors. Our results suggest that EP1R-3R play a minimal role in cancer progression in patients with TCC-UUT. On the other hand, EP4R regulates tumor progression via cancer cell proliferation and MMP-2, distinct from COX-2.


Subject(s)
Carcinoma, Transitional Cell/metabolism , Kidney Neoplasms/metabolism , Kidney Pelvis/metabolism , Receptors, Prostaglandin E/metabolism , Ureteral Neoplasms/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Transitional Cell/blood supply , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/pathology , Cell Proliferation , Cyclooxygenase 2/metabolism , Female , Fluorescent Antibody Technique, Indirect , Humans , Immunoenzyme Techniques , Kidney Neoplasms/blood supply , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Kidney Pelvis/pathology , Male , Microcirculation/metabolism , Microcirculation/pathology , Neoplasm Proteins/metabolism , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Survival Rate , Ureteral Neoplasms/blood supply , Ureteral Neoplasms/mortality , Ureteral Neoplasms/pathology
14.
Clin Cancer Res ; 12(3 Pt 1): 800-6, 2006 Feb 01.
Article in English | MEDLINE | ID: mdl-16467091

ABSTRACT

PURPOSE: Lymph vessel density (LVD) and microvessel density (MVD) correlate with the malignant potential of tumors and patient survival. Vascular endothelial growth factors (VEGF)-A, VEGF-C, and VEGF-D could modulate LVD and MVD. We investigated the clinical and prognostic significance of LVD and MVD on lymphangiogenic and angiogenic function of VEGF-A, VEGF-C, and VEGF-D in human bladder cancer. EXPERIMENTAL DESIGN: We reviewed tissue samples from patients with nonmetastatic bladder cancer who had undergone transurethral resections (n = 126). The densities of D2-40-positive vessels (LVD) and CD34-positive vessels (MVD) were measured by a computer-aided image analysis system. Expression of VEGF-A, VEGF-C, and VEGF-D was examined by immunohistochemistry; survival analyses and their independent roles were investigated using multivariate analysis models. RESULTS: LVD was associated with tumor grade but not with pT stage. LVD was associated with metastasis-free survival (log rank P = 0.039), but was not an independent prognostic factor. Although MVD affected survival, the combination of high LVD and high MVD in tumors was an independent predictor of metastasis-free survival. Although VEGF-C expression was positively associated with both LVD and MVD, VEGF-D was associated only with LVD. VEGF-A expression was associated with MVD in univariate analysis, however, it was not an independent factor. CONCLUSIONS: Lymphangiogenesis and angiogenesis influence metastasis-free survival, and are regulated by VEGF-C and/or VEGF-D. Our results suggest that LVD and MVD are useful tools for the selection of postoperative management and treatment strategies in patients with bladder cancer.


Subject(s)
Lymphangiogenesis , Neovascularization, Pathologic/physiopathology , Urinary Bladder Neoplasms/physiopathology , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor C/genetics , Vascular Endothelial Growth Factor D/genetics , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/analysis , Antibodies, Monoclonal, Murine-Derived , Antigens, CD34/analysis , Female , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Humans , Image Processing, Computer-Assisted , Immunohistochemistry , Male , Middle Aged , Multivariate Analysis , Prognosis , Survival Analysis , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder Neoplasms/genetics , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor D/metabolism
15.
Urology ; 65(6): 1254-8, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15922416

ABSTRACT

OBJECTIVES: To investigate alterations in gap junctional protein, connexin-43 (Cx-43), in the rat detrusor muscle with partial bladder outlet obstruction (P-BOO). Muscle cell actions, such as detrusor contractions, are thought to be synchronized by way of gap junctional intercellular communication. Gap junctions may play an important role in voiding, and P-BOO is a common medical problem. METHODS: A total of 33 female Wistar rats (12 weeks old) were divided into a P-BOO group and a sham-operated control group and were killed at 2, 4, and 8 weeks after surgery. Cystometric investigation, the alteration of gap junction, and Cx-43 protein expression, which compose the gap junction, were examined. RESULTS: The number of gap junctions was decreased in the P-BOO rat bladder. Furthermore, decreased cellular membrane expression of Cx-43 proteins was detected in rat detrusor muscle cells more than 4 weeks after surgery. The gap junctions of the detrusor muscle cell membranes were significantly fewer in number in the P-BOO rats with no detrusor contractions. CONCLUSIONS: These data suggest that the normal signals that contribute to voiding function could be transported directly through the gap junctions. Voiding dysfunction may be caused by the disruption of gap junctional intercellular communication.


Subject(s)
Cell Membrane/metabolism , Connexin 43/metabolism , Gap Junctions/pathology , Urinary Bladder Neck Obstruction/metabolism , Urinary Bladder/metabolism , Animals , Chronic Disease , Female , Immunohistochemistry , Muscle Contraction , Muscle, Smooth/metabolism , Muscle, Smooth/ultrastructure , Rats , Rats, Wistar , Urinary Bladder/physiopathology , Urinary Bladder/ultrastructure , Urinary Bladder Neck Obstruction/pathology , Urinary Bladder Neck Obstruction/physiopathology , Urodynamics
16.
J Urol ; 173(1): 56-60, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15592025

ABSTRACT

PURPOSE: Prostaglandin E2, produced by cyclooxygenase (COX)-2, affects the behavior of tumor cells possibly through 1 of the prostaglandin E2 receptors, the EP4 receptor (EP4R). The relationship between tumor development and EP4R in transitional cell carcinoma of the upper urinary tract (TCC-UUT) has not been fully understood. We determined the relationships between clinicopathological features and prognosis with expressions of COX-2 and EP4R in nonmetastatic TCC-UUT. MATERIALS AND METHODS: We examined expressions of COX-2 and EP4R by immunohistochemical technique in 101 patients. Histological features including tumor grade, pT stage and lymph node metastasis were examined using formalin fixed and paraffin embedded specimens from the radical operation. The predictive values of these expressions of prognosis were investigated by Kaplan-Meier curve and Cox proportional hazards analysis in multivariate model. RESULTS: Expression of COX-2 and EP4R was observed in 46 (45.5%) and 51 (50.5%) cases, respectively. Each expression was significantly associated with pT stage and grade. Patients with co-expression of these proteins had a higher frequency of extra-urinary tract recurrence (33.3%). Postoperative survival time of patients with co-expression of COX-2 and EP4R was significantly shorter than that of patients with other expression patterns (p <0.001). Although COX-2 or EP4R expression was not an independent factor for cause specific survival in a multivariate model, co-expression of these proteins was an independent one (odds ratio 12.26 and p = 0.0038). CONCLUSIONS: Co-expression of COX-2 and EP4R is a potentially useful marker for tumor progression and survival in patients with nonmetastatic TCC-UUT.


Subject(s)
Carcinoma, Transitional Cell/metabolism , Isoenzymes/metabolism , Kidney Neoplasms/metabolism , Kidney Pelvis , Neoplasm Recurrence, Local/metabolism , Prostaglandin-Endoperoxide Synthases/metabolism , Receptors, Prostaglandin E/metabolism , Ureteral Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/mortality , Cyclooxygenase 2 , Female , Humans , Immunohistochemistry , Kidney Neoplasms/mortality , Male , Membrane Proteins , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local/mortality , Prognosis , Proportional Hazards Models , Prostaglandins E/metabolism , Receptors, Prostaglandin E, EP4 Subtype , Ureteral Neoplasms/mortality
17.
Int J Urol ; 11(11): 1016-8, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15509208

ABSTRACT

We report a case of mucinous adenocarcinoma of the renal pelvis associated with bladder carcinoma in situ (CIS). Transitional cell carcinoma (TCC) of the renal pelvis and CIS were also observed adjacent to the adenocarcinoma. Immunohistochemical assessment of the pelvic adenocarcinoma revealed positive expressions for mucin, epithelial membrane antigen, cytokeratin 7, cytokeratin 19 and carcinoembryonal antigen, but not vimentin or chromogranin. Based on the histopathological examinations, the adenocarcinoma of the renal pelvis in the present case may have a similar biological nature to conventional TCC and probably originated by development of pre-existing TCC of the renal pelvis.


Subject(s)
Adenocarcinoma, Mucinous/diagnosis , Carcinoma in Situ/diagnosis , Carcinoma, Transitional Cell/diagnosis , Kidney Neoplasms/diagnosis , Kidney Pelvis/pathology , Neoplasms, Multiple Primary/diagnosis , Urinary Bladder Neoplasms/diagnosis , Adenocarcinoma, Mucinous/metabolism , Adenocarcinoma, Mucinous/therapy , Aged , Carcinoembryonic Antigen/metabolism , Carcinoma in Situ/metabolism , Carcinoma in Situ/therapy , Carcinoma, Transitional Cell/metabolism , Carcinoma, Transitional Cell/therapy , Humans , Keratin-7 , Keratins/metabolism , Kidney Neoplasms/metabolism , Kidney Neoplasms/therapy , Male , Mucin-1/metabolism , Mucins/metabolism , Neoplasms, Multiple Primary/metabolism , Neoplasms, Multiple Primary/therapy , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/therapy
18.
Urology ; 63(6): 1084-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15183955

ABSTRACT

OBJECTIVES: To report our experience with bacille Calmette-Guérin (BCG) perfusion therapy for transitional cell carcinoma in situ of the upper urinary tract. BCG perfusion therapy is widely used to treat transitional cell carcinoma in situ of the upper urinary tract. However, it has not yet been established as a standard treatment. METHODS: Ten patients diagnosed with transitional cell carcinoma in situ of the upper urinary tract were treated with BCG perfusion therapy from January 1990 to May 2002. BCG was instilled weekly for 6 weeks, with a median dose of 65 mg at 1.17 mg/mL (Tokyo 172 strain, dissolved in normal saline). RESULTS: The mean follow-up period was 50.9 months (range 12 to 134). The initial response to therapy was excellent, and cytology became negative in all patients after one course of BCG perfusion. Five patients developed recurrence after 5, 11, 24, 26, and 45 months, and all died after 46, 12, 41, 134, and 79 months, respectively. The mortality rate was 50% and was 100% in those with recurrence. The mean recurrence-free period was 22.2 months (range 5 to 45). Complications included bladder irritation-related symptoms in all patients, fever greater than 38 degrees C (n = 9), hematuria (n = 2), hydronephrosis (n = 2), and lumbago (n = 1) but all were transient and did not affect long-term prognosis. CONCLUSIONS: BCG perfusion therapy for carcinoma in situ of the upper urinary tract is safe, and the short-term response is excellent. However, the long-term results were not satisfactory. Therefore, this therapy should be considered experimental, although it may have potential benefits in delaying progression and possibly providing local control for patients in poor condition. Long-term studies are required for additional evaluation of BCG therapy.


Subject(s)
BCG Vaccine/therapeutic use , Carcinoma in Situ/drug therapy , Carcinoma in Situ/mortality , Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/mortality , Urologic Neoplasms/drug therapy , Urologic Neoplasms/mortality , Administration, Intravesical , Adult , Aged , Aged, 80 and over , BCG Vaccine/adverse effects , Carcinoma, Transitional Cell/secondary , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Hydronephrosis/etiology , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local , Survival Rate , Treatment Outcome , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/mortality
19.
Urology ; 63(3): 602-8, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15028476

ABSTRACT

OBJECTIVES: To investigate the relationship between the expression of matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 and pT stage or survival in patients with transitional cell carcinoma of the upper urinary tract. MMP-2 and MMP-9 are associated with tumor invasion in several malignancies. TIMPs exert an anti-invasive effect by blocking MMP activity. Recent studies have shown, however, that TIMPs can also stimulate cell proliferation and angiogenesis. METHODS: Tumor sections surgically removed from 91 patients were examined for expression of MMP-2, MMP-9, TIMP-1, and TIMP-2 by immunohistochemistry. We also determined the proliferation index and microvessel density in each tumor and investigated the independent roles of these factors in tumor stage and survival using multivariate analysis. RESULTS: Of 91 tissue samples, 50, 51, 45, and 39 were positive for MMP-2, MMP-9, TIMP-1, and TIMP-2 expression, respectively. Tumors positive for MMP-2, MMP-9, and TIMP-1 exhibited a greater proliferation index than tumors with negative expression (P <0.001, P = 0.013, and P <0.001, respectively). The microvessel density of tumors positive for MMP-2 and TIMP-1 was greater than that of negative tumors (P <0.001). The expression of MMP-2, MMP-9, and TIMP-1 was an independent predictor of high pT stage. Cox proportional hazard analysis identified TIMP-1 expression as an independent factor for cause-specific survival (odds ratio 5.2, P = 0.011), similar to microvessel density, pT4, and lymph node metastasis. CONCLUSIONS: TIMP-1 expression correlated with pT stage and was an independent predictor of cause-specific survival. Our results suggest that TIMP-1 expression is a potentially useful tool for the selection of postoperative observation strategies in patients with transitional cell carcinoma of the upper urinary tract.


Subject(s)
Carcinoma, Transitional Cell/enzymology , Kidney Neoplasms/enzymology , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 9/biosynthesis , Neoplasm Proteins/biosynthesis , Tissue Inhibitor of Metalloproteinase-1/biosynthesis , Ureteral Neoplasms/enzymology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Carcinoma, Transitional Cell/blood supply , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/pathology , Cell Division , Enzyme Induction , Female , Gene Expression Regulation, Neoplastic , Humans , Kidney Neoplasms/blood supply , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Kidney Pelvis/pathology , Lymphatic Metastasis , Male , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/genetics , Middle Aged , Neoplasm Proteins/genetics , Neoplasm Staging , Neovascularization, Pathologic/enzymology , Proportional Hazards Models , Retrospective Studies , Survival Analysis , Tissue Inhibitor of Metalloproteinase-1/genetics , Ureteral Neoplasms/blood supply , Ureteral Neoplasms/mortality , Ureteral Neoplasms/pathology
20.
J Neurol Sci ; 217(1): 3-6, 2004 Jan 15.
Article in English | MEDLINE | ID: mdl-14675601

ABSTRACT

OBJECTIVES: Patients with human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) frequently experience voiding dysfunction. In patients with HAM/TSP, the major symptoms are gait disturbance and voiding dysfunction. However, the detailed natural course of voiding function and the management of their urination has not previously been investigated. We examined the correlation between voiding function and clinical features and evaluated the management of urination, in the patients with HAM/TSP. PATIENTS AND METHODS: The voiding function of 47 patients (7 males, 40 females, aged 29-89 years, mean: 60.9 years) with HAM/TSP was analyzed retrospectively. All HAM/TSP patients are positive for HTLV-1. Patients were referred to a neurologist for analysis of bladder function. In the present study, we analyzed their clinical details, age at disease onset, voiding function and alterations in the management of their urination. Furthermore, we investigated the relationship between urological management and the clinical features of HAM/TSP. RESULTS: Of the 47 patients, 20 (42.5%) were able to void with or without drug therapy. Thirty-four (72.3%) experienced clean intermittent self-catheterization (CIC), with 25 of these 34 continuing CIC, 7 changing to voiding and 2 changing to management with the Foley catheter. No relationship was noted between disruption of voiding function and either age or gender. However, significant inverse correlation was observed between the age at disease onset and the time to CIC (r=-0.77, P=0.00001). CONCLUSIONS: These data suggest that the younger a patients is at HAM/TSP onset, the longer voiding function will be maintained.


Subject(s)
Paraparesis, Tropical Spastic/physiopathology , Urination Disorders/etiology , Adult , Age of Onset , Aged , Aged, 80 and over , Female , Follow-Up Studies , Human T-lymphotropic virus 1/pathogenicity , Humans , Male , Middle Aged , Paraparesis, Tropical Spastic/epidemiology , Retrospective Studies , Time Factors , Urinary Catheterization/methods , Urination Disorders/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...